The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

GSK has announced a $1.2 billion deal to acquire efimosfermin alfa from Boston Pharmaceuticals, writes John George for the ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK to buy Boston Pharma’s efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of SLD: London, UK Thursday, May 15, 2025, ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

The new drug, licensed years ago by Novartis AG to closely held Boston Pharmaceuticals, should have benefits beyond any GLP-1 therapy patients are taking, GSK said. GSK shares rose less than 1% in ...